35666-81-0

Basic information

• Product Name: 4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine
• Synonyms: 4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine;4-Morpholineacetonitrile, a,a-diMethyl-;2-Morpholino-2-cyanopropane;alpha,alpha-Dimethyl-4-morpholineacetonitrile
• CAS NO: 35666-81-0
• Molecular Formula: C16H11F3N2S
• Molecular Weight: 320.3321496
• Mol File: 35666-81-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 123-125℃
• Boiling Point: 94℃ (3 Torr)
• Flash Point: 230.7°C
• Appearance: /
• Density: 1.343g/cm³
• Vapor Pressure: 1.45E-08mmHg at 25°C
• Refractive Index: 1.595
• PKA: 2.96±0.10(Predicted)
• CAS DataBase Reference: 4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine(35666-81-0)
• EPA Substance Registry System: 4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine(35666-81-0)

Safety Data

• Hazardous Substances Data: 35666-81-0(Hazardous Substances Data)

Usage

General Description

4-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)benzenamine is a chemical compound with a complex molecular structure. It belongs to the class of aromatic amines and thiazole derivatives. The compound contains a thiazole ring connected to a benzene ring, with a trifluoromethyl substituent attached to the phenyl group. This chemical is commonly used in pharmaceutical and agrochemical industries as a building block for the synthesis of various biologically active compounds and as a potential target for drug discovery and development. Due to its unique structure and potential medicinal properties, this compound is of great interest to researchers in the field of medicinal chemistry and drug design.

InChI:InChI=1/C16H11F3N2S/c17-16(18,19)12-5-1-10(2-6-12)14-9-22-15(21-14)11-3-7-13(20)8-4-11/h1-9H,20H2

Upstream product

• 110-91-8 morpholine 
• 19355-69-2 2-amino-2-cyanopropane 
• 7677-24-9 trimethylsilyl cyanide 
• 67-64-1 acetone 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 477531-69-4 di(morpholino)cyanoborane 
• 151-50-8 potassium cyanide 

Downstream Products

• 100617-69-4 4-(1-methyl-1-phenyl-ethyl)-morpholine 
• 1004-14-4 4-isopropyl-morpholine 
• 494773-23-8 4-(2-(4-bromophenyl)propan-2-yl)morpholine 
• 173336-43-1 2-methyl-2-morpholinopropan-1-amine 
• 62317-19-5 1-(morpholin-4-yl)cyclopentanecarbonitrile 
• 94576-68-8 α-Morpholino-p-phenyl-isobutyrophenon 

Relevant articles and documents

Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B)

KDM5B (also known as PLU-1 and JARID1B) is 2-oxoglutarate and Fe2+ dependent oxygenase that acts as a histone H3K4 demethylase, which is a key participant in inhibiting the expression of tumor suppressors as a drug target. Here, we present the discovery of pyrazole derivatives compound 5 by structure-based virtual screening and biochemical screening with IC50 of 9.320 μM against KDM5B, and its subsequent optimization to give 1-(4-methoxyphenyl)-N-(2-methyl-2-morpholinopropyl)-3-phenyl-1H-pyrazole-4-carboxamide (27 ab), a potent KDM5B inhibitor with IC50 of 0.0244 μM. In MKN45 cells, compound 27 ab can bind and stabilize KDM5B and induce the accumulation of H3K4me2/3, bona fide substrates of KDM5B, while keep the amount of H3K4me1, H3K9me2/3 and H3K27me2 without change. Further biological study also indicated that compound 27 ab is a potent cellular active KDM5B inhibitor that can inhibit MKN45 cell proliferation, wound healing and migration. In sum, our finding gives a novel structure for the discovery of KDM5B inhibitor and targeting KDM5B may be a new therapeutic strategy for gastric cancer treatment.

One-stage synthesis of adamantyl-containing α-aminonitriles

Reactions of 2-adamantan-2-one, acetone cyanohydrin, and amine lead to the formation of substituted 2-amino-2-cyanoadamantanes. The reaction is of a general character as has been proved by examples on a series of ketones and amines and it proceeds through

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.